Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Enzon Pharmaceuticals, Inc. (OTC: ENZN).

Full DD Report for ENZN

You must become a subscriber to view this report.


Recent News from (OTC: ENZN)

Tracking Carl Icahn's Portfolio - Q2 2018 Update
This article is part of a series that provides an ongoing analysis of the changes made to Carl Icahn’s 13F portfolio on a quarterly basis. It is based on Icahn’s regulatory 13F Form filed on 08/14/2018. Please visit our Tracking Carl Icahn’s Portfolio series to get a...
Source: SeekingAlpha
Date: September, 03 2018 05:15
Tracking Carl Icahn's Portfolio - Q1 2018 Update
This article is part of a series that provides an ongoing analysis of the changes made to Carl Icahn's 13F portfolio on a quarterly basis. It is based on Icahn's regulatory 13F Form filed on 05/15/2018. Please visit our Tracking Carl Icahn's Portfolio series to get an idea of his investmen...
Source: SeekingAlpha
Date: May, 21 2018 05:46
Independent Research on Trending Growth Companies: Vet Online Supply and Enzon Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / March 5 , 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of Vet Online Supply, Inc. ( OTC PINK: VTNL) and Enzon Pharmaceuticals Inc. (OTCQX: ENZN), including recent technical analysis and consolidated fundamental ...
Source: ACCESSWIRE IA
Date: March, 05 2018 08:30
Tracking Carl Icahn's Portfolio - Q4 2017 Update
This article is part of a series that provides an ongoing analysis of the changes made to Carl Icahn’s 13F portfolio on a quarterly basis. It is based on Icahn’s regulatory 13F Form filed on 02/14/2018. Please visit our Tracking Carl Icahn’s Portfolio series to get an ...
Source: SeekingAlpha
Date: February, 20 2018 04:54
Tracking Carl Icahn's Portfolio - Q3 2017 Update
This article is part of a series that provides an ongoing analysis of the changes made to Carl Icahn’s 13F portfolio on a quarterly basis. It is based on Icahn’s regulatory 13F Form filed on 11/14/2017. Please visit our Tracking Carl Icahn’s Portfolio series to get an ...
Source: SeekingAlpha
Date: November, 19 2017 04:24

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-100.2210.2210.230.22113,246
2018-12-070.220.2210.2250.2210,198
2018-12-060.2210.220.2250.226,600
2018-12-050.230.220.230.226,664
2018-12-040.230.220.230.226,664

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-106,06713,24645.8025Short
2018-12-061,1006,60016.6667Cover
2018-12-041616,6642.4160Cover
2018-12-0342,70056,16876.0219Short
2018-11-3023,60024,53896.1774Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ENZN.


About Enzon Pharmaceuticals, Inc. (OTC: ENZN)

Logo for Enzon Pharmaceuticals, Inc. (OTC: ENZN)

Enzon Pharmaceuticals, Inc. receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products, namely, PegIntron R , Sylatron R , Macugen R and CIMZIA R .

 

Contact Information

 

 

Current Management

  • Andrew Rackear / CEO, Secretary
  • Richard L. Feinstein / CFO
  • Jonathan Christodoro / Chairman, Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • Odysseas Kostas / Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • Jennifer McNealey / Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member

Current Share Structure

  • Market Cap: $12,822,237 - 03/15/2018
  • Authorized: 170,000,000 - 03/12/2018
  • Issue and Outstanding: 44,214,610 - 03/12/2018
  • Float: 44,083,157 - 03/31/2017

 


Recent Filings from (OTC: ENZN)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: April, 25 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: April, 13 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: April, 12 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 21 2018
Certification of termination of registration of a class of security under Section 12(g) or notice of suspension of duty to file reports under Section 13 and 15(d) of the Act Section 12 (g).
Filing Type: 15-12GFiling Source: edgar
Filing Date: February, 13 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 09 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: January, 22 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 09 2017

 

 


Daily Technical Chart for (OTC: ENZN)

Daily Technical Chart for (OTC: ENZN)


Stay tuned for daily updates and more on (OTC: ENZN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ENZN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ENZN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ENZN and does not buy, sell, or trade any shares of ENZN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/